August 12, 2024 03:38 PM EDTUpdated 05:58 PM
China
Pharma
Manufacturing

Pres­sure from an­ti-Chi­na leg­is­la­tion be­gins to rip­ple through bio­phar­ma

Zachary Brennan

Senior Editor

A lat­est round of SEC fil­ings from bio­phar­ma com­pa­nies shows at least a dozen com­pa­nies high­light­ing the Biose­cure Act as a ma­jor in­com­ing risk, as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: A male con­tra­cep­tive may pre­vent 99% of preg­nan­cies. Now it’s up to a small biotech to fin­ish test­ing it

Roche's dual GLP-1/GIP re­sults show promis­ing weight loss, but al­so high rates of vom­it­ing

House pass­es Biose­cure Act, send­ing Chi­nese biotech ban to Sen­ate

Ex­clu­sive: Bain scoops up $3B for fourth life sci­ences fund af­ter hand­ful of M&A deals

Roivant un­veils its next deal, hop­ing for TL1A-sized po­ten­tial from a shelved Bay­er lung dis­ease ther­a­py

Io­n­is’ $500M of­fer­ing; Terns aims to raise $125M 

A service from the Financial Times